Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe^® Safety Switch

Bellicum Pharmaceuticals, Inc. and The University of Texas MD Anderson Cancer Center announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum’s CaspaCIDe® safety switch and related technologies, and the use of rimiducid, an agent used to activate the safety switch.